Stay updated on Nivolumab +/- Ipilimumab in NECs Clinical Trial
Sign up to get notified when there's something new on the Nivolumab +/- Ipilimumab in NECs Clinical Trial page.

Latest updates to the Nivolumab +/- Ipilimumab in NECs Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior Notice about lapse in government funding and Revision: v3.4.1 from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA general site notice about potential delays due to a lapse in government funding was added, and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedMinor UI/text updates: added a 'Show glossary' option; updated footer labels to 'Last Update Submitted that Met QC Criteria' (from 'Last Update Submitted that met QC Criteria') and to 'No FEAR Act Data' (from 'No FEAR Act data'); updated the revision tag to 'Revision: v3.4.0' (from 'Revision: v3.3.4'). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 has been added, replacing Revision: v3.3.3. This metadata update does not affect the study details, eligibility criteria, or outcomes.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter now shows Revision: v3.3.3, and the HHS Vulnerability Disclosure and Revision: v3.3.2 elements were removed.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page now indicates Revision: v3.3.2; the content shown (study details, criteria, and results) appears unchanged compared to the previous revision. No new content or functional changes are visible in the screenshot.SummaryDifference0.1%

Stay in the know with updates to Nivolumab +/- Ipilimumab in NECs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab +/- Ipilimumab in NECs Clinical Trial page.